About ABL Diagnostics
ABL Diagnostics is a company based in Woippy (France) founded in 2015. The company has 19 employees as of December 31, 2024. ABL Diagnostics offers products and services including DeepChek® Assay, UltraGene Assay, and Nadis®. ABL Diagnostics operates in a competitive market with competitors including Souzhou Ribo Life Science, Altis Biosystems, Senzo, PathoQuest and Hememics Biotechnologies, among others.
- Headquarter Woippy, France
- Employees 19 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abl Diagnostics Sa
-
Annual Revenue
$5.54 M (USD)-5.03as on Dec 31, 2024
-
Net Profit
$296.26 K (USD)424.58as on Dec 31, 2024
-
EBITDA
$328.3 K (USD)0as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
19
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ABL Diagnostics
ABL Diagnostics is a publicly listed company on the EURONEXT with ticker symbol ABLD in France, operating in the Finance sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ABL Diagnostics
ABL Diagnostics offers a comprehensive portfolio of products and services, including DeepChek® Assay, UltraGene Assay, and Nadis®.
Tool for whole genome HIV-1 genotyping through sequencing.
Detects SARS-CoV-2 and other viruses via real-time PCR.
Electronic medical record system for lab automation.
Funding Insights of ABL Diagnostics
Detailed funding history for ABL Diagnostics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ABL Diagnostics
Investment portfolio details for ABL Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ABL Diagnostics
Detailed financials for ABL Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abl Diagnostics Comparisons
Peer comparison for ABL Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ABL Diagnostics
ABL Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Souzhou Ribo Life Science, Altis Biosystems, Senzo, PathoQuest and Hememics Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nucleic acid drugs are developed via RNA interference technology.
|
|
| Locked | Locked | Locked |
Provider of invitro platform for drug testing
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic devices for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Next-generation sequencing is provided for microbiology testing applications.
|
|
| Locked | Locked | Locked |
Biopreservation platform for mammalian cells and biologics is developed.
|
|
| Locked | Locked | Locked |
Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.
|
Detailed competitors of ABL Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abl Diagnostics
Complete news archive for ABL Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ABL Diagnostics
ABL Diagnostics was founded in 2015.
ABL Diagnostics is headquartered in Woippy, France. It is registered at Woippy, Grand Est, France.
Ronan Boulme is the current CEO of ABL Diagnostics.
As of Dec 31, 2024, the latest employee count at ABL Diagnostics is 19.
Annual revenue of ABL Diagnostics is $5.54M as on Dec 31, 2024.
ABL Diagnostics was founded in 2015 in Woippy, France, within the biotechnology sector focused on infectious disease diagnostics. Molecular biology assays and kits, including UltraGene for detection and DeepChek for genotyping via DNA sequencing, are provided to microbiology laboratories. Real-time PCR assays, instruments, consumables, and downstream analysis software are also supplied to support diagnostic operations across Europe.
ABL Diagnostics's top competitors include Altis Biosystems, Souzhou Ribo Life Science and Quantalife.
ABL Diagnostics offers DeepChek® Assay, UltraGene Assay, and Nadis®.
Yes, ABL Diagnostics is publicly traded on EURONEXT under the ticker symbol ABLD.
The ticker symbol of ABL Diagnostics is ABLD on EURONEXT.